ICCC - ImmuCell Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.15
-0.00 (-0.02%)
As of 2:55PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.15
Open6.15
Bid6.15 x 800
Ask6.37 x 3100
Day's Range6.05 - 6.44
52 Week Range5.55 - 9.30
Volume6,623
Avg. Volume7,525
Market Cap44.332M
Beta (3Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateMay 12, 2017 - May 15, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ICCC earnings conference call or presentation 14-May-19 1:00pm GMT

    Q1 2019 ImmuCell Corp Earnings Call

  • Benzinga2 months ago

    The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...

  • GlobeNewswire2 months ago

    ImmuCell Announces Unaudited Financial Results for First Quarter of 2019

    PORTLAND, Maine, May 13, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire2 months ago

    ImmuCell to Announce Unaudited Financial Results for First Quarter of 2019

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle - will report unaudited financial results for the quarter ended March 31, 2019 after the market closes on Monday, May 13, 2019.  The Company has scheduled a conference call the next day, Tuesday, May 14, 2019, at 9:00 AM ET to review the results. ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle.  ImmuCell markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef livestock, and is in the late stages of developing Re-Tain™, a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry.  Press releases and other information about the Company are available at: http://www.immucell.com.

  • GlobeNewswire4 months ago

    ImmuCell Corporation Announces Closing of $9 Million Public Offering of Common Stock

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the closing of its previously announced underwritten public offering of 1,636,364 shares of common stock at a price to the public of $5.50 per share. All of the shares of common stock were offered by ImmuCell. The net proceeds from the offering are approximately $8.3 million, after deducting underwriting discounts and other estimated expenses incurred in connection with the offering.

  • GlobeNewswire4 months ago

    ImmuCell Corporation Announces Pricing of $9.0 Million Public Offering of Common Stock

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the pricing of its previously announced underwritten public offering of 1,636,364 shares of common stock of the Company at a price to the public of $5.50 per share. ImmuCell expects to receive aggregate gross proceeds of approximately $9.0 million from the offering.  All of the shares of common stock are being offered by ImmuCell.  The offering is expected to close on or about March 29, 2019, subject to customary closing conditions. Craig-Hallum Capital Group is acting as sole managing underwriter for the offering.

  • GlobeNewswire4 months ago

    ImmuCell Corporation Announces Commencement of Public Offering of Common Stock

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by ImmuCell. Craig-Hallum Capital Group is acting as sole managing underwriter for the offering.

  • GuruFocus.com4 months ago

    ImmuCell Corp (ICCC) Files 10-K for the Fiscal Year Ended on December 31, 2018

    ImmuCell Corp is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. ImmuCell Corp had annual average EBITDA growth of 5.30% over the past five years. Warning! GuruFocus has detected 6 Warning Signs with ICCC.

  • Do Directors Own ImmuCell Corporation (NASDAQ:ICCC) Shares?
    Simply Wall St.4 months ago

    Do Directors Own ImmuCell Corporation (NASDAQ:ICCC) Shares?

    If you want to know who really controls ImmuCell Corporation (NASDAQ:ICCC), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders,Read More...

  • GlobeNewswire5 months ago

    ImmuCell Announces Submission of Manufacturing Technical Section for its Purified Nisin Product

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a critical milestone in the development of Re-Tain™, its Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The Company has made its first phased submission to the U.S. Food and Drug Administration (FDA) of the manufacturing technical section (known as the Chemistry, Manufacturing and Controls (CMC) Technical Section) with respect to the Nisin Drug Substance under the Company’s New Animal Drug Application (NADA).  This submission is subject to a six-month review period and will be followed by a second phased submission covering the Nisin Drug Product, which is also subject to a six-month review period before anticipated product approval can occur.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...

  • GlobeNewswire5 months ago

    ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2018

    PORTLAND, Maine, Feb. 13, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire5 months ago

    ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2018

    PORTLAND, Maine, Feb. 06, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of ICCC earnings conference call or presentation 14-Nov-18 2:00pm GMT

    Q3 2018 ImmuCell Corp Earnings Call

  • GlobeNewswire7 months ago

    ImmuCell Announces USDA Approval of Dual-Force™ First Defense®

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that the USDA has issued a product license for Dual-Force™ First Defense®. The gel tube delivery format is a preferred administration route for some, as an alternative to the Company’s longstanding First Defense® capsule. “Our goal is to formulate our efficacious colostrum antibodies into a variety of formats so that our customers can choose the option that works best for their operations,” commented Michael F. Brigham, President and CEO.

  • GlobeNewswire8 months ago

    Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    ImmuCell Announces Financial Results for Third Quarter of 2018

    PORTLAND, Maine, Nov. 13, 2018 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire8 months ago

    ImmuCell to Participate at 9th Annual Craig-Hallum Alpha Select Conference

    PORTLAND, Maine, Nov. 08, 2018 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire8 months ago

    ImmuCell to Announce Financial Results for Third Quarter of 2018

    Conference Call Scheduled for Wednesday, November 14, 2018 at 9:00 AM ET PORTLAND, Maine, Nov. 07, 2018 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a.

  • Simply Wall St.10 months ago

    Could ImmuCell Corporation’s (NASDAQ:ICCC) Investor Composition Impacts Your Returns?

    The big shareholder groups in ImmuCell Corporation (NASDAQ:ICCC) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable Read More...

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of ICCC earnings conference call or presentation 14-Aug-18 1:00pm GMT

    Q2 2018 ImmuCell Corp Earnings Call

  • ACCESSWIRE11 months ago

    ImmuCell Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / ImmuCell Corporation (NASDAQ: ICCC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 9:00 AM Eastern Time. ...